Phase II study of 9-hydroxy-2N-methylellipticinium acetate
- 1 February 1984
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 20 (2), 243-247
- https://doi.org/10.1016/0277-5379(84)90190-1
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study)European Journal of Cancer and Clinical Oncology, 1982
- Phase I clinical study of 9-hydroxy-2N-methyl-ellipticinium acetate (NSC-264137) administered on a 5-day i.v. scheduleEuropean Journal of Cancer and Clinical Oncology, 1982
- HYDROXY-9-METHYL-2-ELLIPTICINIUM FOR OSSEOUS METASTASES FROM BREAST-CANCER - A 5-YEAR EXPERIENCE1982
- Drug Dependent Red Cell Antibodies and Intravascular Haemolysis Occurring in Patients Treated with 9 Hydroxy‐Methyl‐EllipticiniumBritish Journal of Haematology, 1980
- METABOLISM AND DISPOSITION STUDIES OF 9-HYDROXYELLIPTICINE AND 2-METHYL-9-HYDROXYELLIPTICINIUM ACETATE IN ANIMALS1980